A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

NCT05094804 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Tumor, Solid
Malignant Neoplasm
Metastatic Cancer
Advanced Solid Tumor
Non Small Cell Lung Cancer
Melanoma
Head and Neck Squamous Cell Carcinoma
Leiomyosarcoma
Liposarcoma

Interventions

DRUG: OR2805
DRUG: Cemiplimab
DRUG: Docetaxel

Sponsor

OncoResponse, Inc.